Table 5.

Change in the %PV in the cardiac allograft vasculopathy area according to clinical factors

	Initial %PV	Follow-up %PV	Δ %PVa	P-value of within factorb	P-value of between factorc
Sex					0.566
Male (n = 12)	22.4 ± 5.3	30.6 ± 10.9	8.2 ± 7.2	0.016
Female (n = 7)	26.3 ± 9.4	36.5 ± 11.4	10.1 ± 6.3	<0.001
Years after HTX					0.001
≤2 years (n = 8)	20.4 ± 3.3	24.0 ± 4.9	3.6 ± 2.2	0.008
>2 years (n = 11)	26.4 ± 8.2	39.1 ± 10.0	12.8 ± 63	0.001
Donor age					0.186
≤30 years (n = 10)	22.2 ± 5.43	29.2 ± 9.6	7.0 ± 6.7	0.002
>30 years (n = 9)	25.7 ± 8.6	36.81 ± 1.9	11.1 ± 6.5	0.004
Diabetes					0.550
Yes (n = 6)	20.3 ± 3.8	27.8 ± 3.7	7.5 ± 4.3	0.031
No (n = 13)	25.5 ± 7.8	35.1 ± 12.7	9.6 ± 7.7	<0.001
Dyslipidaemia					0.299
Yes (n = 11)	25.4 ± 7.4	35.8 ± 11.6	10.3 ± 7.6	0.001
No (n = 8)	21.7 ± 6.4	28.7 ± 9.5	7.0 ± 5.2	0.008
Renal insufficiency					0.547
Yes (n = 11)	24.7 ± 8.0	34.5 ± 12.0	9.7 ± 6.4	0.001
No (n = 8)	22.6 ± 5.9	30.4 ± 10.2	7.8 ± 4.5	0.002
CMV infection					0.511
Yes (n = 6)	22.9 ± 3.2	29.8 ± 6.8	6.9 ± 4.1	0.031
No (n = 13)	24.3 ± 8.4	34.1 ± 12.6	9.9 ± 7.6	<0.001
ISHLT rejection grade ≥2					0.118
Yes (n = 7)	23.7 ± 6.7	35.2 ± 11.2	11.5 ± 7.1	0.016
No (n = 12)	23.9 ± 7.6	31.4 ± 11.3	7.4 ± 6.4	<0.001
Underlying disease					0.336
Ischaemic CMP (n = 3)	21.1 ± 3.3	26.5 ± 7.4	5.4 ± 4.5	0.250
Non-ischaemic CMP (n = 16)	24.4 ± 7.6	33.9 ± 11.5	9.6 ± 7.0	<0.001
Maintenance regimen					0.895
Sirolimus (n = 13)	23.2 ± 5.1	32.5 ± 10.0	9.3 ± 7.4	<0.001
Calcineurin inhibitors (n = 6)	25.3 ± 10.8	33.5 ± 14.3	8.2 ± 5.7	0.031

CMV, cytomegalovirus; CMP, cardiomyopathy; HTX, heart transplantation; ISHLT, International Society for Heart and Lung Transplantation; %PV, per cent plaque volume.

^aDifference between follow-up %PV and initial %PV.

^bP-values are from the Wilcoxon signed rank test.

^cP-values are from comparing the Δ %PV between factors with the Mann–Whitney U test.